secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001625101-22-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Kevin Danahy as Chief Commercial Officer, effective Feb 14
--------------------------------------------------------------------------------

- Kevin Danahy named CCO; receives $395,000 base salary, 50% target bonus.
- Granted 300,000 stock options at $6.41/share (Feb 14 closing price), 4-year vesting.
- Danahy has 20+ years in medtech; previously President at Solmetex, VP at Zimmer Biomet.
- Appointment is an inducement award under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000162510122000008/0001625101-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000162510122000008/plse-20220209x8k.htm
  HTML page:      https://secwatch.observer/filing/0001625101-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer